Business Context and Reporting Period
Company: Nanophase Technologies Corporation (Note: Metadata listed "SOLESENCE, INC." but filing text confirms Nanophase Technologies Corporation).
Reporting Period: Quarterly period ended March 31, 2001 (Form 10-Q).
Business Overview: The Company develops and sells nanocrystalline materials for commercial production. Since inception, it has incurred cumulative losses of approximately $30.1 million and has historically funded operations through equity issuances. Revenue is primarily derived from the healthcare and catalyst markets.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Total Revenue | $1,071,924 | $618,921 |
| Product Revenue | $980,174 | $487,171 |
| Net Loss | $(1,119,283) | $(1,434,559) |
| Loss Per Share (Basic/Diluted) | $(0.08) | $(0.11) |
| Operating Cash Flow | $(1,436,413) | $(1,954,976) |
| Cash & Investments | $14,878,578 | $17,304,757 (Dec 31, 2000) |
| Total Debt (Short + Long Term) | $1,044,228 | $1,113,300 (Dec 31, 2000) |
| Inventory (Net) | $1,409,927 | $892,674 (Dec 31, 2000) |
Margins: Gross margin improved as a percentage of revenue due to increased sales volume and favorable product mix, though the Company remains unprofitable with a significant operating loss.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 73% year-over-year, driven primarily by a 101% increase in product revenue.
- Expense Management: Research and development (R&D) expenses decreased 26% to $437,670, attributed to lower hiring and bonus costs compared to the prior year. Conversely, Selling, General, and Administrative (SG&A) expenses increased 22% to $1.14 million due to costs associated with a new facility, insurance, and printing.
- Capital Expenditures: Significant increase in capital spending to $965,804 (vs. $53,972 in 2000) for manufacturing facility expansion and equipment.
- Inventory Build: Net inventory increased by approximately $517,000 during the quarter to support production.
Outlook, Risks, and Contingencies
Management Commentary: Management expects to increase R&D expenses for the remainder of 2001 to expand product lines. The Company believes current cash, investments, and interest income are adequate to fund current operating plans but may seek additional financing in the future, which could be dilutive.
Legal Proceedings:
- Settled: A consolidated complaint regarding the 1997 IPO was settled for $4,025,000, fully funded by directors and officers liability insurance. The case was dismissed with prejudice in March 2001.
- Pending: A separate complaint by former preferred stockholders alleging fraud regarding the IPO remains pending. The Company intends to defend vigorously but cannot predict the outcome or potential material adverse effects.
Risks: Key risks include uncertain market demand, dependence on a limited number of customers, limited manufacturing capacity, and the potential expiration of net operating loss carryforwards (approx. $33.2 million) if not utilized by 2015.
Investor Verification Checklist
- Liquidity Runway: Verify if the $14.9 million in cash and investments is sufficient given the $1.4 million quarterly operating cash burn and planned capital expenditures.
- Revenue Concentration: Confirm the identity and stability of the "limited number of key customers" mentioned in the risk factors.
- Legal Exposure: Monitor the status of the pending preferred stockholder lawsuit and potential liability exposure beyond the settled amount.
- Inventory Valuation: Assess the $1.4 million inventory balance against actual sales velocity to ensure no future write-downs are necessary.
- Dilution Risk: Review the Company's capital requirements to determine the likelihood of future equity offerings.